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Abstract Imatinib has represented a revolution in the treat-
ment of chronic myeloid leukemia (CML), inducing an over-
all survival never seen with previous therapies. However, with
the commonly used dosage of 400 mg, one third of the treated
patients does not reach the criteria associated with an optimal
outcome and could potentially benefit from a different treat-
ment strategy. Several trials exploring modified imatinib-
based treatments or second-generation tyrosine-kinase as
front-line therapy have been performed. In some studies,
high-dose (800 mg per day) or dose-adapted imatinib or ima-
tinib plus interferon was reported to be able to induce better
cytogenetic and molecular responses compared with standard-
dose imatinib, although no improvements in progression-free
survival (PFS) or overall survival (OS) have been so far re-
ported. At the moment, these approaches are still considered
investigational. On the other side, on the basis of their capacity
to induce very fast and deep molecular responses, including
major molecular responses (MMRs) and the newly defined
very deep molecular responses MR4 and MR4.5, and to pre-
vent at least part of the early progressions to AP/BC that still
occur during the first 2–3 years from diagnosis, dasatinib and
nilotinib have been approved and registered by FDA and
EMA as the first-line therapy for CML patients, opening the
possibility to use different therapeutic strategies for newly
diagnosed CML patients and a consequent intense debate
among hematologists.
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Introduction
The impressive rates of complete cytogenetic responses
(CCyRs) achieved the consequent long-term overall survival
(OS) observed in the treated patients, and the good tolerability
led imatinib, the first tyrosine-kinase inhibitor (TKI) used for
the therapy of chronic myeloid leukemia (CML), to become
the standard of care and the most widely used frontline therapy
for CML patients in chronic phase at the dosage of 400 mg per
day [1, 2]. The most relevant data of the 8-year follow-up of
the IRIS study that have also been confirmed by other studies
and by independent retrospective analysis performed on pa-
tients outside clinical trials show a cumulative CCyR rate of
83 % and an estimated OS rate of 85 %, which is far better
from what was observed before the introduction of this drug
[3–6]. This result may be ascribed to a substantial decrease in
the number of the progressions to accelerated phase or blast
crisis observed in the patients treated with imatinib. All re-
cords indeed suggest that progressions to a more advanced
phase of the disease still represent the major cause of death
for CML patients, being still incurable in most cases even in
the tyrosine-kinase inhibitor (TKI) era [7]. With imatinib ther-
apy, the occurrence of progression drops from an expected
rate of approximately 15 % per year to a rate of 2–3 % per
year, and only for the first 2–3 years of treatment as during the
subsequent years, events of progression are really occasional
[3]. This is certainly due to the great reduction of the leukemic
mass observed in most of the imatinib-treated patient that in
some few cases can also result in an apparent disappearance of
the leukemic clone, but also to the fact that imatinib, inhibiting
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the BCR-ABL tyrosine kinase (TK) activity that plays a major
role in determining the genomic instability of the leukemic
cells, may per se be able to slow the propensity to progress [8].
It has been demonstrated that the patients who better ben-
efit from the TKI therapy with imatinib are those who achieve
and maintain CCyR for at least 2 years, as in these cases, the
OS is similar to that of a control population without leukemia
[9]. On the other side, various analyses have shown that pa-
tients who do not achieve good cytogenetic or molecular re-
sponses to imatinib at defined time points have a worse out-
come, characterized by an increased risk of relapse, of pro-
gression and of death [10, 11]. Based on these principles, a
panel of CML experts on behalf of the European Leukemia
Net (ELN) as wel l as members of the Nat ional
Comprehensive Cancer Network (NCCN) have previously
established and more recently revised treatment milestones
to be achieved during CML treatment with TKIs [12, 13].
This obviously implies that, to optimize CML treatment with
TKIs, an appropriate and timely follow-up with cytogenetic
and standardized molecular methods of adequate reliability is
needed [14–16]. In particular, molecular monitoring of BCR-
ABL transcript levels by real-time quantitative PCR (RQ
PCR) is progressively becoming the most useful and precise
way to monitor CML patients. With respect to conventional
cytogenetic analysis, RQ PCR can not only allow to monitor
the first steps of reduction of the leukemic burden occurring
within the first months of TKI therapy, but it may also allow to
estimate the amount of the residual disease once CCyR is
achieved, as the sensitivity that can be reached with the pres-
ent RQ PCR procedures in a sample of good quality is in most
cases between 1×10−4/10−5 that corresponds to an amount
between 2 and 3 logs below the threshold of the achievement
of CCyR [14]. According to the established international scale
(IS), the relevant BCR-ABL% to be achieved are 1 % (2-log
reduction with respect to the median BCR-ABL amount pres-
ent at diagnosis and that roughly corresponds to the threshold
of CCyR), 0.10 % BCR-ABL (major molecular response
(MMR)), and 0.01% and to 0.0032%BCR-ABL correspond-
ing, respectively, toMR4 (4-log reduction) andMR4.5 (4.5-log
reduction) [14–16].
Probably, even in our days, the attainment of CCyR or 1 %
BCR-ABL can still be considered the most significant re-
sponse to target, as this goal has been demonstrated to be
associated to the highest probability of long-term survival
for CML patients [17–19]. On the other side, several sets of
data did not appear to support the notion that deeper re-
sponses, as the achievement of level of BCR-ABLIS ≤0.1 %
(MMR) may indeed improve OS relative to achieve CCyR
without MMR [17, 18]. More recently, however, a 4-year
landmark analysis performed within the context of the
German CML-study IV suggests that the patients who after
4 years were able to achieve a stable MR4.5 molecular re-
sponse, at 8 years, show a statistically significant better
survival with respect to those patients who have simply
achieved CCyR, but not MMR [19]. If these results will be
confirmed, MR4.5 will represent a new molecular predictor of
long-term outcome. In any case, it has been clearly established
by several clinical studies that a stable deep molecular re-
sponse (at least MR4 or even better MR4.5) is requested to
obtain a long-lasting treatment-free remission (TFR) that is
progressively becoming the new treatment goal for CML pa-
tients [20, 21]. Thus, the achievements of MMR and of MR4.5
in addition to CCyR and MMR are appealing targets to pur-
suit, as they predict for more durable and stable responses and
can also open the possibility to try to stop the therapy.
It is noteworthy that many studies, particularly in more
recent years, have indicated that early cytogenetic and molec-
ular responses within the first year of therapy represent the
strongest prognostic parameters [18, 22–24], not only in terms
of OS, progression-free survival (PFS), or event free survival
(EFS) but also in terms of possibility of achieving deeper
molecular responses and therefore the possibility of
discontinuing treatment without molecular relapse(TFR)
[20]. Based on these observations, the last editions of the
ELN and NCCN recommendations have modified with re-
spect to the past the time points at which the expected re-
sponse goals should be met to match the criteria for optimal
response [12, 13]. Whereas, previously, only hematologic re-
mission and some degree of cytogenetic response were ex-
pected after 3 months of TKI therapy, partial cytogenetic re-
sponse (PCyR) after 6 months and CCyR after 1 year, in the
last editions of both ELN and NCCN recommendations, to be
considered Boptimal responders^, the patients should at least
be in partial cytogenetic response (PCyR) and/or below the
roughly corresponding 10%IS BCR-ABL threshold after
3 months of therapy, at least in CCyR and/or below the 1%IS
BCR-ABL level after 6 months of therapy and at least in
MMR after 1 year of therapy and thereafter show a continuous
decline of the BCR-ABL level until the achievement of deeper
responses like MR4 or MR4,5 [12, 13]. Indeed, many studies
suggest that the most clinically relevant target to be achieved
during TKI therapy is represented by a reduction of the BCR-
ABL transcript level below 10%IS at 3 months, as this is as-
sociated with a high statistically significant difference in terms
of OS and PFS [18, 22–24].
Even simply based on this parameter, it appears that ap-
proximately one third of CML patients do not show an opti-
mal response to imatinib therapy and they are therefore facing
a statistically significantly higher risk of an inferior outcome
in terms of EFS, PFS, and also OS (approximately 80 % at
5 years with respect to >95 % of those below 10% BCR-ABL
at 3 months) [18, 22–24]. Actually, it is true that most of these
patients (approximately 80 %) will only show a delayed re-
sponse and that they will simply require a switch to treatment
with a second-generation TKI to achieve an optimal response
in approximately 40–50 % of the cases [25, 26]. However, it
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should also be considered that approximately 15–20 % of
them in a short time will progress to a more advanced phase
of the disease and will die [18, 22–24]. In any case, several
reports including IRIS have shown that after 8 years from
diagnosis, only approximately 55–60 % of the patients who
started with imatinib are still on treatment with this drug [3, 5].
In addition to the cases of failure, of progression, and of death,
the reasons for discontinuation include also 10–12 % of
patients who show adverse events (AEs) and are intolerant
to imatinib treatment and should be moved to the treatment
with another TKI [3].
In is also noteworthy that the percentage of the patients
who do not respond optimally to imatinib may vary according
to the initial clinical and hematological features that determine
their initial risk category, as established by Sokal’s, and Euro
and also by themore recent EUTOS score [27–29]. In the IRIS
study, patients with low-, intermediate-, or high-risk Sokal’s
score showed significantly different response rates as 5-year
CCyR (89, 82, and 69 %, respectively: P<0.001) and
progression to advanced disease (3, 8, and 17 %, re-
spectively: P=0.002) [1].
Based on all these considerations, several clinical trials
aiming to improve the first-line treatment of patients with
chronic phase CML have been performed or are at present
ongoing. The therapeutic strategies that are tested include
the first-line administration of the second-generation TKIs
originally used as second-line therapy or modified imatinib-
based regimens, as higher dosages of imatinib from the start or
combinations of imatinib with other drugs, namely, interferon-
alpha (IFN-α). At present, only the use of the second-
generation TKIs nilotinib at the dosage of 300 mg BID and
of dasatinib 100 mg OD have been approved and registered as
the first-line therapy in several countries and are also included
in the ELN and NCCN recommendations, whereas the other
two quoted options still remain investigational [12]. As pa-
tients with CP CML are now having a very long survival and
very long follow-ups are consequently required before the
efficacy of these alternative treatment options could be mea-
sured in terms of OS, important surrogate markers as the rates
of CCyR, MMR, MR4, and MR4.5 achieved at relevant time-
points, the more recent parameters of early molecular response
(EMR) as well as the more traditional event free survival
(EFS) and progression-free survival (PFS) parameters have
been frequently used as way to evaluate the relative responses
and to compare results. However, in order to get a correct
information, it is important to consider that the methods to
asses and to report the rate of responses can sometimes vary
and that the definitions of the EFS and PFS may change
substantially according to the protocol in different trials
and may therefore introduce bias difficult to perceive in
the comparative evaluation of the results [30, 31].
Considering this potential limitation, we will now re-
view the main treatment options to imatinib 400 mg
OD as the first-line therapy for CP CML patients cur-
rently available or explored in clinical trials.
Second-generation TKIs in first-line treatment
Following the success of imatinib, three different second-
generation BCR-ABL inhibitors, more potent than imatinib,
have been tested as the first-line therapy to try to overcome the
residual resistance still shown by some patients to imatinib
and to further improve the outcome of CP-CML patients
[32]. These drugs were TKIs already approved as second-
line therapy for imatinib-intolerant or imatinib-resistant pa-
tients, namely, dasatinib (Sprycel, Bristol-Myers Squibb)
[33], a dual BCR-ABL and SRC inhibitor, nilotinib
(Tasigna, Novartis) [34], a potent and more selective BCR-
ABL inhibitor and bosutinib (Bosulif, Pfizer) another potent
dual BCR-ABL and SRC inhibitor [35].
All these drugs when used as second-line therapy
showed a distinct, but substantially good toxicity profile
and were able to induce a CCyR rate of 40–50 % in
patients with primary or secondary resistance to imatinib
[25, 26], also when this was due to the presence of clones
with most of the BCR-ABL mutations able to confer resis-
tance to imatinib, with some notable exceptions like the T315I
mutation [36].
The efficacy and the toxicity of nilotinib and dasatinib as
the first-line therapy were initially assessed in phase 2 studies
that have now reached a rather long follow-up [37–39]. The
results obtained in 73 newly-diagnosed CP-CML patients
treated with nilotinib 400 mg twice a day by the GIMEMA
CML working party showed CCyR achievement at 3 months
in 78 % of the patients and in 96 % at 6 months, whereas the
MMR rates observed were 52 and 66 %, respectively, at the
same time points and 85 % at 12 months [37]. Similarly,
results of 100 newly diagnosed CML patients treated at the
MD Anderson Cancer Center with nilotinib 400 mg twice
daily (BID) showed, with a median follow-up 29 months
(range 1–73), a cumulative CCyR rate of 93 % a rate of
MMR of 73 % and a CMR rate (defined according to the
previous ELN criteria as undetectable hybrid transcripts with
a sensitivity of at least 10−4/−5) of 33 % [37]. At the same
institution, 86 newly-diagnosed patients were treated with
dasatinib 50 mg twice daily (BID) or 100 mg QD [39]. With
a median follow-up of 24 months, most patients achieved a
rapid CCyR (94 % at 6 months), with a cumulative CCyR
ratio of 98 %. After 12 and 18 months, MMR was achieved
by 71 and 79 % of patients [39]. The toxicity profile with
dasatinib was also favorable, with a better tolerability with
dasatinib QD vs BID dosing.
ENESTnd is a phase 3, randomized, open-label, multicen-
ter study comparing the efficacy and safety of nilotinib with
imatinib in patients with newly diagnosed CML that has now
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reached the fifth year of follow-up [40, 41]. The trial included
846 patients randomly assigned 1:1:1 to nilotinib 300 mg BID
(n=282), nilotinib 400 mg BID (n=281), or imatinib 400 mg/
day (n=283). MMR at 12 months was the primary endpoint.
Patients were also stratified by Sokal’s risk score, which re-
sulted in equal distributions of low-, intermediate-, and high-
risk Sokal’s scores in each arm of the trial. Efficacy results
were presented in the intent-to-treat (ITT) population. The
MMR rate at 12 months was significantly higher for nilotinib
300 mg BID (44 %, P<0.0001) and nilotinib 400 mg BID
(43 %, P<0.0001) than for imatinib (22 %). As this was the
primary endpoint of the study, nilotinib 300 mg BID was
approved by FDA and EMA and it is now registered as the
first-line therapy in several countries. Responses were rapidly
achieved with nilotinib, with 6-month MMR rates of 33, 30,
and 12% for nilotinib 300mgBID, nilotinib 400mgBID, and
imatinib, respectively. These higher responses were also asso-
ciated with significantly fewer progressions to AP/BC with
nilotinib than with imatinib as already observed during the
first year of the study [39]. After a minimum follow-up of
5 years, rates of MMR and MR4.5 continue to be significantly
higher in both nilotinib arms versus the imatinib arm (MMR
77 and 77.2 versus 60 % and MR4.5 53.5 and 52.3 versus
31.4 %), with more than half of the nilotinib-treated patients
achieving MR4.5 by 5 years [40]. When considering progres-
sion events occurring during treatment and after treatment
discontinuation, rates of freedom from progression to AP/
BC remain statistically higher in the nilotinib-treated patients
(96.3 and 97.8 % for nilotinib versus 92.1 % imatinib).
However, although estimated rates of OS are higher in the
nilotinib arms versus the imatinib arm (93.7 % nilotinib
300 mg BID, 96.2 % nilotinib 400 mg BID, and 91.7%ima-
tinib), at the moment, they do not reach a statistically signif-
icant difference. The frequency of adverse events (AEs) lead-
ing to discontinuation was lowest in the nilotinib 300 mg BID
arm (12.2 %), followed by the imatinib arm (13.9 %) and the
nilotinib 400 mg BID arm (19.9 %) [40]. However, the occur-
rence of cardiovascular events, which have been frequently
reported in association with nilotinib therapy, has been more
frequently observed in both nilotinib arms that in the imatinib
arm, although these events (including all definitions of differ-
ent gravity and also cerebrovascular events and PAD, periph-
eral arterial disease) are definitelymore frequent in the 400mg
BID arm than in the 300 mg BID arm (7.5 % in the nilotinib
300 mg BID, 13.4 % nilotinib 400 mg BID versus 91.7 in the
imatinib arm) [40]. In conclusion, the 5-year follow-up data
confirm the sustained efficacy of frontline nilotinib over ima-
tinib as front-line therapy including achievement of earlier and
deeper molecular responses and increased freedom from pro-
gression to AP/BC. These results can be particularly relevant
also in light of the reported option for some patients attaining a
very low level of residual disease (MR4.5 or lower) to discon-
tinue the therapy without recurrence of the disease at least for
a relevant period of time [20]. It is also relevant that, compar-
ing only nilotinib 300 mg BID and imatinib 400 mg OD at
3 months, 91 % of patients in the nilotinib arm versus 67 % in
the imatinib arm achieved BCR-ABL transcript levels ≤10
and 56 % versus only 16 % of patients achieved already
BCR-ABL transcript levels ≤1 % [23]. The initial molecular
response correlates also with progression to AP/BC and with
OS in both treatment arms, as among the patients who
achieved ≤10 % BCR-ABL at 3 months, only 3 progressed
on treatment whereas 9 of 111 patients who achieved >10% at
3 months progressed. These results clearly show the relevance
to evaluate early molecular response at 3 months [23].
Dasision is a phase 3, randomized, open-label, multicenter
study comparing the efficacy and safety of dasatinib 100 mg
OD as the first-line therapy with respect to that of imatinib
[42]. Even this study has now achieved a minimum follow-up
of 5 years [43]. Patients with newly diagnosed CML-CP were
stratified according to the Euro risk score and randomly
assigned to dasatinib 100 mg/day or imatinib 400 mg/day.
Confirmed CCyR by 12 months was the primary endpoint
of the study and by 12 months was significantly higher for
dasatinib (83 %, P<0.001) than for imatinib (72 %), allowing
also this drug to be approved as the first-line therapy by FDA
and EMA. The best cumulative MMR rate by 12 months was
also significantly higher for dasatinib (46 %, P<0.0001) than
for imatinib (28 %) [42]. Fewer progressions to accelerated
phase or blast crisis (AP/BC) with dasatinib (1.9 %) than with
imatinib (3.5 %) were already observed in the first report of
these data [42]. After 5 years, molecular response rates con-
tinue to be higher for dasatinib compared with imatinib (rates
of MMR 76 vs 64%, P=0.002 and rates of MR4.5 42 vs 33%,
P=0.025). Transformations to AP/BC on study or after dis-
continuation were lower with dasatinib (n=12/259; 4.6 %)
compared with imatinib (n=19/260; 7.3 %). However, 5-
year PFS and OS rates were similar across treatment arms
(PFS 85 % dasatinib, 86 % imatinib; OS 91 % dasatinib,
90 % imatinib) [43]. A higher proportion of patients on
dasatinib achieved BCR-ABL ≤10 % at 3 months (84 %)
compared with those on imatinib (64 %). Patients who
achieved BCR-ABL ≤10% versus >10% at 3 months showed
improved PFS and OS and lower rates of transformation to
AP/BP (PFS 89 vs 72 %, P=0.0014; OS 94 vs 81 %,
P=0.0028; transformation n=6/198 [3 %] vs n=5/37
[14 %]) and imatinib (PFS 93 vs 72 %, P<0.0001; OS 95 vs
81 %, P=0.0003; transformation n=5/154 3 % vs n=13/85,
15 %) [24]. Concerning the AEs of dasatinib, the total inci-
dence of pleural effusion after 5 years is 29 %, but most cases
were grade 1 or 2 (67 out of 74) and discontinuation of
dasatinib due to pleural effusion occurred in only 15 patients
(6 % overall and 20 % of pts who experienced a pleural effu-
sion). Arterial ischemic events were not common, occurring in
12 pts (5 %) on dasatinib and 6 pts (2 %) on imatinib [43].
More recently, however, one investigator-initiated study
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comparing dasatinib 100 mg OD vs imatinib 400 mg OD,
although showing that the proportion of patients achieving
CCyR was superior with dasatinib (84 % vs 69 %) as well
as the 12-month molecular responses (MMR 53 vs. 35 %,
P=0.049; MR4 25 vs. 10 %, P=0.038), did not show any
advantage in terms PFS as well as in terms of OS [44].
Finally, BELA is a phase 3 multicenter study comparing
the efficacy and safety of bosutinib 500 mg OD with that of
imatinib 400 mg OD [45]. In this study, CCyR by 12 months
that was the primary endpoint of the study did not result to be
significantly higher for bosutinib (70 %), compared with ima-
tinib (68%), and this did not allow bosutinib to be approved as
the first-line therapy. These results have been jeopardized by
the high rate of discontinuation mainly due to non hematolog-
ic drug-related AEs that occurred in the bosutinib arm (19 %
rate of discontinuation in the bosutinib armwith respect to 5%
in the imatinib arm) and, in particular, the high rates of dis-
continuation due to diarrhea on bosutinib. However, MMR
rates by 12 months were significantly higher for bosutinib
(39 % bosutinib versus 26 % imatinib, P=0.002) and there
were numerically fewer progressions to AP/BCwith bosutinib
(2 %) than with imatinib (4 %) [45].
In conclusion, because of their higher inhibition capacity of
the BCR-ABL TK, second-generation TKIs demonstrate
some aspects of superiority compared to imatinib 400 mg
OD as initial therapy for CML. This is revealed by a faster
time to cytogenetic and molecular responses, with more pa-
tients achieving BCR-ABL ≤10 % at 3 months and by
sustained higher cumulative responses, particularly by higher
rates of very deep molecular responses like MR4 and MR4.5.
The immediate clinical advantage of their use as front-line
therapy could be represented by a lower rate of transforma-
tion, whereas on a longer run the advantage could be repre-
sented by a faster achievement of conditions allowing to reach
and maintain a TFR state. However, 5-year OS are not statis-
tically different with respect to imatinib and some observed
long-term toxicity effects, like a higher rate of cardiovascular
events, could raise concerns for their use, particularly in some
categories of patients [46].
High-dose imatinib for first-line treatment
Current treatment guidelines for CML recommend first-line
therapy with imatinib at a dose of 400 mg/day. However this
dosage may not be optimal for patients characterized by a
genetic predisposition to a lower efficiency of the OCT-1
transporter, a pump regulating the intracellular influx and con-
centration of imatinib, who, on the contrary, could significant-
ly benefit from higher initial imatinib dose [47]. Furthermore,
phase 1 dose-finding trials demonstrated no dose-limiting tox-
icities at imatinib doses up to 1000 mg/day, and a dose–re-
sponse relationship was observed and the best results with
imatinib 400 mg were obtained when imatinib plasma con-
centration was at least 1000 μM/L [48]. This explains also
why responses to imatinib are also so dependent on a perfect
adherence to dosage and to scheduled treatment [49].
Based on these considerations, shortly after the approval of
imatinib, a number of single-arm phase 2 studies were started
to assess the efficacy and the safety of high-dose imatinib
(800 mg) administration. These data compared favorably with
historical controls [50–53]. In particular, the BRationale and
Insight for Gleevec High-Dose Therapy^ (RIGHT) trial [52,
53], testing high-dose imatinib at 800 mg/day in previously
untreated CML patients, showed a trend (although not statis-
tically significant, P=0.07), toward improved transformation
free survival (TFS) with respect to historical controls treated
with standard dose in the same institution [53]. An analysis of
the kinetics of response in the RIGHT trial showed that 44 %
of patients achieved a major MMR within 6 months of initi-
ating therapy [52]. Compared with data from the IRIS trial [1],
which showed a 6-month MMR rate of 21 % with standard-
dose imatinib, these data suggest that high-dose imatinib can
achieve more rapid responses. Another study, the TIDEL trial,
used imatinib 600 mg/day to explore the concept of high-dose
imatinib as initial therapy for CML in early CP [54]. When
these data were compared with the imatinib arm of the IRIS
trial, the CCyR rate was significantly improved with the
higher dose (P<0.001). However, the results obtained from
ongoing randomized studies comparing first-line treatment
with standard and high-dose imatinib are contrasting at the
moment. The BTyrosine kinase inhibitor OPtimization and
Selectivity^ trial (TOPS) is a phase III study involving 476
patients randomized in a 2:1 ratio to receive 800 or 400 mg/
day imatinib [55]. In initial results, patients in the 800-mg arm
achieved more rapid responses than the 400-mg arm at early
time point months (3–6 months), although no significant dif-
ference was observed at 12 months (CCyR 70 vs 66 %, P=
0.35; MMR 46 vs 40%, P=0.20). A non significant trend was
reported in patients with high Sokal scores for MMR rates at
12 months (41 vs 46 % for 800 vs 400 mg, P=0.16). After
24 months of follow-up, no significant differences were re-
ported in EFS, PFS, or OS. However, the lack of overall ben-
efit with higher dose may be due in part to the frequent dose-
reductions and treatment interruptions when starting with
higher doses in this multicenter trial, as comparing patients
in the high-dose imatinib arm with dose intensity (DI)
≥600 mg/day for the first 12 months vs dose intensity
<600 mg/day, the results were statistically better for patients
with DI ≥600 mg/day (CCyR rates at 12 months 89.6 vs
70.3 %, P<0.000; MMR rates at 12 months 62.4 vs 34.1 %,
P<0.0001; MMR rates at 18 months 75.2 vs 40.3 %,
P<0.0001; time to MMR faster, P<0.0001; duration of
MMR longer, P=0.0141). The ELN (Nordic countries, Italy,
Turkey, Israel) study compared 400 versus 800 mg/day ima-
tinib in 215 high-Sokal-risk patients, with a primary endpoint
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of CCyR at 12 months [56]. Although the results were not
statistically significant, a clear trend toward higher rates of
MMR with 800 mg/day compared with 400 mg/day was ob-
served, MMR rate was 49 % in the high-dose arm compared
with 41 % in the standard-dose arm [56]. The sample size
selection, the fact that most of the patients treated with high-
dose imatinib required a substantial dose decrease and, finally,
the fact that the number of dropouts in the high-dose arm
(18 %) was slightly higher than in the 400 mg arm could
explain the lack of statistical significance in the high-risk pa-
tients in this trial [56].
Although these data do not apparently support the use of
imatinib 800 mg as first-line treatment in newly diagnosed CP
CML, more recently, in the Study IV trial of German CML
Study Group, in which patients were randomized to receive
imatinib 400 mg/day or 800 mg/day alone, or imatinib
400 mg/day in combination with interferon (IFN) alpha, a
higher rate of MMR at 12 months was observed with
tolerability-adapted imatinib 800 mg than with imatinib
400 mg (59 vs 44 %; P<0.001). Median dose in the 800-mg
arm was 628 mg/day, suggesting that treatment of early-phase
CML with imatinib can be optimized and that early high-dose
therapy followed by rapid adaptation to good tolerability can
increase the rate of MMR at 12 months that in turn has been
shown to be associated with improved survival [4].
Recently, these data have been confirmed by a randomized
study comparing the rates of molecular, hematological, and
cytogenetic response to IM400 vs. imatinib 400 mg twice
daily (IM800) in which dose adjustments were allowed to
maximize retention on study [57]. Molecular response (MR)
at 12 months was deeper in the IM800 arm (4-log reduction of
BCR-ABL1 mRNA 25 vs. 10 % of patients, P=0.038; 3-log
reduction 53 vs. 35 %, P=0.049). Furthermore, in both arms,
few patients relapsed, progressed, or died, but both PFS
(P=0.048) and RFS (relapse-free survival) (P=0.031) were
superior for IM800 [57].
Combination therapy: imatinib plus interferon- alpha
Because of the established clinical benefit of IFN in CML
treatment, combination therapy between this drug and imatin-
ib always appeared appealing and it is under investigation in a
number of clinical trials. In a phase 2 GIMEMA study of
imatinib 400 mg/day plus PEG-IFNα2b 50–150 μg/week,
CCyR and MMR rates were 70 and 47 % at 12 months, with
a probability of maintaining CCyR at 5 years in responding
patients of 94 % [58]. However, compliance to IFN was poor,
with 87 % of patients discontinuing IFN within 2 years [58].
Some large randomized phase 3 trials are comparing imatinib
monotherapy with combination treatment. In the open-label
French SPIRIT trial, patients were randomized 1:1:1:1 to re-
ceive imatinib 400 mg/day, imatinib 600 mg/day, imatinib
400 mg/day plus cytarabine, or imatinib 400 mg/day plus
pegylated interferon alpha (PEG–IFNα2a) [59]. A potential
advantage for imatinib/IFN treatment was first observed in
18-month MMR (41 vs 52 vs 53 vs 62 %; P=0.0001) and
deep molecular response (4-log reduction of BCR-ABL tran-
scripts, CMR4) (4 vs 7 vs 5 vs 15 %; P=0.0013) rates and
reconfirmed at later times [59]. However, further follow-up of
SPIRIT is needed to establish whether these early differences
confer a long-term survival advantage. Grade 3–4 neutropenia
and/or thrombocytopenia during the first year was higher for
combination arms (imatinib/cytarabine 41 %, imatinib/IFN
40 %) than in monotherapy arms (400 mg 8 %, 600 mg
14 %) [59]. Overall, 45 % of the patients discontinued IFN
during the first 12 months. Interestingly, the duration of treat-
ment with IFN had an impact on responses: in patients who
have been treated for less than 4 months as compare to more
than 12 months, rate of MMR, optimal molecular response
MR4, and undetectable minimal residual disease increased
from 48 to 82 %, 23 to 49 %, and 8 to 20 %, respectively
[59]. A rather similar comparison has been performed within
the German CML Study Group (Study IV), with an arm in
which patients were receiving imatinib 400 mg/day in combi-
nation with unpegilated IFNα2beta [4]. With respect to ima-
tinib 400 mg/day alone, 12-month CCyR rates were similar,
52 % for imatinib and 51 % for imatinib plus IFN, and 12-
month MMR rates were 30 and 35 %, respectively [4]. After
5 years of follow-up, no difference was reported between arms
in progression-free survival (PFS) or overall survival (OS) [4].
In a third trial performed by the Nordic CML study group,
newly diagnosed chronic-phase CML patients with a low-
or intermediate-Sokal-risk score and in imatinib-induced
complete hematologic remission were randomized either
to continue imatinib 400 mg/day or to receive a combination
of pegylated IFN-α2b 50 μg weekly and imatinib 400 mg/day
[60]. In the combination arm, 34 patients (61 %) discontinued
PEGeg-IFN-α2b, most because of toxicity. The MMR rate
at 12 months was significantly higher in the imatinib
plus PEGeg-IFN-α2b arm (82 %) compared with the imatinib
monotherapy arm (54 %; intention-to-treat, P=0.002) and the
MMR rate increased with the duration of PEGeg-IFN-α2b
treatment (<12-week MMR rate 67 %, >12-week MMR rate
91 %) [60]. Finally, to determine whether adding PEGeg-
IFN-α2b and GM-CSF to high-dose imatinib may further
improve the cytogenetic and molecular response rates in
CML patients, 94 patients were treated with imatinib
800 mg/day for the first 6 months and then randomized to
continue high-dose imatinib alone or in combination with
PEGeg-IFN-α2b at the dosage of 0.5 μg/kg per week and
GM-CSF 125 mg/m2 three times weekly [61]. With a median
follow-up of 54 months, no differences in the CCyR, MMR,
and CMR rates were observed. However, the potential benefit
of adding PEGeg-IFN-α2b and GM-CSF to imatinib may
have been limited by the fact that, due to adverse events, all
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patients enrolled in the PEGeg-IFN-α2b arm discontinued this
drug [61].
Reasons for these different findings between the French
SPIRIT trial and the Nordic trial on one side and the
German CML Study IV and the MDAnderson trial on the
other side are not clear at the moment; however, multiple
differences present in the protocols (i.e., the type of IFN used,
patient populations, and trial designs) need to be considered.
In conclusion, although literature data are still rather con-
troversial on the real efficacy of the association of imatinib
plus IFN and higher rates of discontinuation are recorded due
to IFN toxicity, the association of IFN and TKIs still appears
particularly appealing for many investigators in view of a
potential long-term effect on a higher rate of TFR. Indeed, a
big study (CMLV) has been recently initiated by the German
CML Study Group to explore the safety and the efficacy of the
association between nilotinib and IFNα2a.
Conclusions
The choice of first-line treatment of CML in chronic phase is
at the moment one of the hottest topics of debate among he-
matologists around the world. Imatinib has represented a fun-
damental step for the treatment of CML patients, totally
changing their survival perspectives, and it has been able to
save the lives of an incredible number of patients. Although
changing from place to place, the cost of the drug is not low
and this has certainly reduced the use of this drug in
some low-income countries. The impact of this problem
has been in part alleviated by the action of international
charity programs supported by pharma companies like
the GIPAP program by Novartis. As it already happened
in some countries, the treatment with imatinib will cer-
tainly become more widely accessible when, after the
imatinib patent expiration, the introduction of generic
compounds will decrease the cost of the drug.
In spite of this, it should be recognized that the re-
sults that could be obtained with imatinib at the dosage
of 400 mg/day are non optimal in approximately one
third of the newly diagnosed CML patients and many
investigational trials have been therefore started to try to
further optimize first-line therapy [3]. For the moment,
trials aiming to improve the outcome by increasing the
imatinib dosage or by combining imatinib with IFN
have provided in part contradictory results. However,
the results obtained by the use of a tolerability-adapted
imatinib dosage observed in the German CML study IV
are very promising and have been recently confirmed by an-
other independent study [57]. To be recommended, however,
as standard first-line therapy for newly diagnosed CML pa-
tients, additional trials to clearly confirm this assumption are
desired. On the other side, the use of the more potent second-
generation TKIs dasatinib and nilotinib as initial treatment for
CML, although not producing a significantly better OS with
respect to standard-dose imatinib therapy, has been approved
and registered by the FDA and EMA entities as potential
alternatives to imatinib as first-line therapy for CML, mainly
because of the faster and deeper responses induced by these
drugs and for their capacity to prevent at least part the early
progressions to AP/BC that may still occur during the first 2 to
3 years from diagnosis [40, 42]. This latter point, however, as
mentioned, has not been confirmed for dasatinib in a second
investigator initiated study and needs to be further explored
[44].
The approval of nilotinib 300 mg/day and of dasatinib
100 mg/day in addition to imatinib as first-line therapy has
introduced different therapeutic options for clinicians to treat
newly diagnosed CML patients and, as specified also by the
2013 ELN guidelines where no preferential use of one of the
three approved drugs is recommended, this gives to clinician
the possibility to tailor the treatment according to the patients’
characteristics [12, 13]. Therefore, the use of the second-
generation TKIs for all patients from the beginning or their
use only for some subgroups of patients with high risk of
progression or to initially start with imatinib 400 mg and then
to switch to a second-generation TKI as soon as a non-optimal
response is seen or only when an overt failure is recorded, this
is at the moment mainly left to the choice of the doctor, who
has of course to consider the balance between efficacy, toxic-
ity, and affordable cost for each individual patient. Trials test-
ing all possible therapeutic strategies are however presently
ongoing and their results will certainly help clinicians to fur-
ther make their decision.
At the moment, in the choice of initial CML therapy, we
must consider also that the optimal endpoint to be pursued
may vary from patient to patient. For an elderly patient, the
attainment of an overall survival probability overlapping that
of the corresponding control population without CML could
be a sufficient target, but the expectations could be different
for a younger patient who, aiming at a definitive cure, can also
accept a more demanding therapeutic approach. This explains
why CMR and the more precise definitions of molecular de-
grees of residual disease recently introduced (like MR4 and
MR4.5) have become the primary endpoint of some clinical
trials and also why, in the attempt to define parameters useful
to identify patients with a higher probability of not relapsing
after discontinuation, the number of studies with the final aim
to increase CMR rates in view of possible therapy discontin-
uation is progressively increasing. As a fast initial response
may be highly predictive of the patients’ final outcome, a
more intense schedule for monitoring the response with cyto-
genetic and/or molecular analysis within the first semester of
therapy is advisable even in common clinical practice,
as clearly stated in the ELN and NCCN recommenda-
tions [12, 13].
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